Home > Keywords > Thématique > Science

Science

Articles

  • Vect-Horus Appoints Dr Jean-Manuel PEAN as Chief Scientific Officer
    3 April 2023, by Elodie DORMES

    Marseille, April 3rd, 2023 - VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the appointment of Dr Jean-Manuel Péan as Chief Scientific Officer. In this role, he will lead the Company’s scientific programs and will be a member of the Management Committee of Vect-Horus.
    Alexandre Tokay, CEO and co-founder of VECT-HORUS said: "We are very pleased to have Jean-Manuel as our (…)

  • TIDES Europe: Oligonucleotide & Peptide Therapeutics in AMSTERDAM
    31 October 2019, by Elodie DORMES

    Dr Guillaume JACQUOT will present "Targeted Drug Delivery to the CNS and Peripheral Tissues Using the VECTrans® Innovative Technology" during the TIDES Europe, 12-15 November 2019.

  • Two new patents protecting VECTrans® technology issued in several major countries
    28 January 2019, by Jonathan NOWAK

    Press release Communiqué de presse
    VECT-HORUS, a biotechnology company that designs and develops peptide vectors for addressing drugs or imaging agents to the brain and other organs, announces the strengthening of its patent portfolio with the granting of two patents in several major countries and particularly in the United States.
    These two patents protect peptide vectors that facilitate the targeting of drugs or imaging agents to organs, including the brain. Entitled “Peptide (…)

  • Vect-Horus successfully completes the VECtoBrain project
    28 January 2019, by Jonathan NOWAK

    Ths project was supported from 2009 to 2013 by the Agence Nationale de la Recherche (ANR) BiotecS Call 2009.
    The project was coordinated by VECT-HORUS (Dr. Guillaume Jacquot) and involved the UMR7259 laboratory (CNRS and Aix-Marseille University, Director Dr Michel Khrestchatisky), the U705 laboratory (Director, Pr. Jean-Michel Scherrmann) of INSERM and the SIMOPRO laboratory (Director Dr. Vincent Dive) of the CEA.
    This project also received support (label) from the EUROBIOMED Biocluster.

  • Vect-Horus validates the potential of its peptide vectors to transport proteins or antibodies, across the blood-brain barrier via receptor mediated transport
    28 January 2019, by Jonathan NOWAK

    (Molino et al., 2017, The FASEB Journal)
    www.fasebj.org/content/early/2017/01/19/fj.201600827R.abstract

  • ECMED EU-GliaPhD international conference in MALTA
    28 January 2019, by Jonathan NOWAK

    Michel Khrestchatisky and Grigorios Kyriatzis (Early Stage Researcher, ESR), both members of the ITN Marie Curie project ECMED will participate in the ECMED EU-GliaPhD international conference organized in Malta, April 29 to May 2, 2018. Michel Khrestchatisky will give a talk on the ongoing projects of his group and biotechnology partner Vect-Horus, also member of the ECMED consortium, while Grigorios Kyriatzis presented results of his ongoing PhD project.

  • Vect-Horus demonstrates the high versatility of its peptide-vectors library for a targeted delivery of small molecules and protein cargos
    28 January 2019, by Jonathan NOWAK

    Identification and characterization of highly versatile peptide-vectors that bind non-competitively to the low-density lipoprotein receptor for in vivo targeting and delivery of small molecules and protein cargos.
    Marion David, Pascaline Lécorché, Maxime Masse, Aude Faucon, Karima Abouzid, Nicolas Gaudin, Karine Varini, Fanny Gassiot, Géraldine Ferracci, Guillaume Jacquot, Patrick Vlieghe, Michel Khrestchatisky
    http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0191052 (…)

  • Neurotensin, vectorised by VECT-HORUS, is the first drug-candidate in neuroprotective hypothermia
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS starts the regulatory preclinical development of VH-N439, positioned as a first-in-class neuroprotective agent in brain ischemia Neurotensin is a neuropeptide with global hypothermic potential when administered directly into the brain, but unable to cross the blood-brain barrier (BBB) when administrated alone systemically. The Company has developed VH-N439, a new chemical entity based on the conjugation of one of its peptide-vectors to an analogue of neurotensin.
    Using in vivo (…)

  • Oligonucleotides for CNS Congress from February 22-24, 2021
    2 February 2021, by Elodie DORMES

    Dr Michel KHRESTCHATISKY will join the session dealing with “Exploring Extra-Hepatic Delivery to Relevant Targets within the CNS & Muscle” and give a talk to describe the use of VECT-HORUS “Molecular Vectors for Targeted Delivery of Oligonucleotides”.

  • Vect-Horus will present at Delivery of Macromolecules, June 8, 2022
    30 May 2022, by Elodie DORMES

    Guillaume JACQUOT, Head of Intracellular Trafficking & Translational Research, will give a talk on this occasion.